No Data
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
Regeneron Pharma Is Maintained at Outperform by Oppenheimer
Regeneron Pharmaceuticals Analyst Ratings
Oppenheimer Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,000
Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment
Express News | Regeneron - Dupixent (Dupilumab) Approved in European Union as First and Only Medicine for Young Children With Eosinophilic Esophagitis
No Data
No Data
